JP7212956B2 - 皮膚障害の処置用のピロロピリジン-アニリン化合物 - Google Patents

皮膚障害の処置用のピロロピリジン-アニリン化合物 Download PDF

Info

Publication number
JP7212956B2
JP7212956B2 JP2020514156A JP2020514156A JP7212956B2 JP 7212956 B2 JP7212956 B2 JP 7212956B2 JP 2020514156 A JP2020514156 A JP 2020514156A JP 2020514156 A JP2020514156 A JP 2020514156A JP 7212956 B2 JP7212956 B2 JP 7212956B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
compounds
mek
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520995A5 (cg-RX-API-DMAC7.html
JP2020520995A (ja
Inventor
ジョン キンケイド
マシュー ダンクトン
Original Assignee
エヌフレクション セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌフレクション セラピューティクス インコーポレイテッド filed Critical エヌフレクション セラピューティクス インコーポレイテッド
Publication of JP2020520995A publication Critical patent/JP2020520995A/ja
Publication of JP2020520995A5 publication Critical patent/JP2020520995A5/ja
Application granted granted Critical
Publication of JP7212956B2 publication Critical patent/JP7212956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020514156A 2017-05-19 2018-05-18 皮膚障害の処置用のピロロピリジン-アニリン化合物 Active JP7212956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US62/508,997 2017-05-19
US201862663202P 2018-04-26 2018-04-26
US62/663,202 2018-04-26
PCT/US2018/033547 WO2018213810A1 (en) 2017-05-19 2018-05-18 Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Publications (3)

Publication Number Publication Date
JP2020520995A JP2020520995A (ja) 2020-07-16
JP2020520995A5 JP2020520995A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7212956B2 true JP7212956B2 (ja) 2023-01-26

Family

ID=62620966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514156A Active JP7212956B2 (ja) 2017-05-19 2018-05-18 皮膚障害の処置用のピロロピリジン-アニリン化合物

Country Status (16)

Country Link
US (4) US11161845B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624796B1 (cg-RX-API-DMAC7.html)
JP (1) JP7212956B2 (cg-RX-API-DMAC7.html)
KR (1) KR102642411B1 (cg-RX-API-DMAC7.html)
CN (1) CN111065393B (cg-RX-API-DMAC7.html)
AU (1) AU2018270295B2 (cg-RX-API-DMAC7.html)
CA (1) CA3063536A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624796T3 (cg-RX-API-DMAC7.html)
ES (1) ES3030506T3 (cg-RX-API-DMAC7.html)
FI (1) FI3624796T3 (cg-RX-API-DMAC7.html)
IL (1) IL270752B (cg-RX-API-DMAC7.html)
MA (1) MA49141A (cg-RX-API-DMAC7.html)
MX (2) MX389965B (cg-RX-API-DMAC7.html)
PL (1) PL3624796T3 (cg-RX-API-DMAC7.html)
PT (1) PT3624796T (cg-RX-API-DMAC7.html)
WO (1) WO2018213810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
JP7212956B2 (ja) * 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
JP2023547040A (ja) * 2020-09-24 2023-11-09 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン-アニリン化合物による、認知機能不全の処置方法
AU2022210443A1 (en) * 2021-01-21 2023-09-07 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds
CN117157065A (zh) * 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
AU2022398467A1 (en) * 2021-11-23 2024-06-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2008148034A1 (en) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
JP2009525317A (ja) 2006-01-31 2009-07-09 ユセベ ファルマ ソシエテ アノニム Mek阻害剤としてのチエノピリジン誘導体
JP2010511626A (ja) 2006-11-30 2010-04-15 ジェネンテック インコーポレイテッド アザ−インドリル化合物及び使用方法
CN105384754A (zh) 2014-09-02 2016-03-09 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006083979A2 (en) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
JP2009525317A (ja) 2006-01-31 2009-07-09 ユセベ ファルマ ソシエテ アノニム Mek阻害剤としてのチエノピリジン誘導体
JP2010511626A (ja) 2006-11-30 2010-04-15 ジェネンテック インコーポレイテッド アザ−インドリル化合物及び使用方法
WO2008148034A1 (en) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
CN105384754A (zh) 2014-09-02 2016-03-09 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters,2012年,22(7),2411-2414
橘高敦史,創薬科学・医薬化学,2007年,p.142-50

Also Published As

Publication number Publication date
AU2018270295B2 (en) 2022-03-03
MA49141A (fr) 2020-03-25
US20250388580A1 (en) 2025-12-25
DK3624796T3 (da) 2025-06-02
US20250034137A1 (en) 2025-01-30
US11161845B2 (en) 2021-11-02
CN111065393A (zh) 2020-04-24
PT3624796T (pt) 2025-06-02
MX2019013561A (es) 2022-02-09
KR102642411B1 (ko) 2024-02-28
MX389965B (es) 2025-03-20
WO2018213810A1 (en) 2018-11-22
KR20200013239A (ko) 2020-02-06
US12428418B2 (en) 2025-09-30
JP2020520995A (ja) 2020-07-16
EP3624796A1 (en) 2020-03-25
AU2018270295A1 (en) 2019-12-05
ES3030506T3 (en) 2025-06-30
IL270752B (en) 2022-06-01
FI3624796T3 (fi) 2025-06-11
US12065439B2 (en) 2024-08-20
CN111065393B (zh) 2023-08-18
US20200165243A1 (en) 2020-05-28
PL3624796T3 (pl) 2025-06-30
EP3624796B1 (en) 2025-03-19
MX2022001697A (es) 2022-04-07
IL270752A (en) 2020-01-30
CA3063536A1 (en) 2018-11-22
US20220033399A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US12428418B2 (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
JP7237941B2 (ja) 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
JP7546297B2 (ja) 皮膚障害の処置のためのチエニル-アニリン化合物
JP7393808B2 (ja) 皮膚障害の処置のためのナフチリジノン-アニリン化合物
CN113473978B (zh) 用于治疗皮肤疾病氰基芳烃-苯胺化合物
HK40026703B (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders
HK40026703A (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230106

R150 Certificate of patent or registration of utility model

Ref document number: 7212956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250